Association of Persistent Symptoms after Lyme Neuroborreliosis and Increased Levels of Interferon-α in Blood.

Bogovič P IFN-α Kastrin A Korva M Lyme disease Lyme neuroborreliosis Ogrinc K Rojko T Slovenia Suggested citation for this article: Hernández SA United States blood et al. Association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon-α in blood. Emerg Infect Dis. 2023 Jun [date cited]. https://doi.org/10.3201/eid2906.221685 immune response increased levels inflammation interferon-alpha persistent symptoms post‒Lyme disease symptoms tick-borne infections vector-borne infections zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
06 2023
Historique:
medline: 22 5 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: ppublish

Résumé

Patients who have Lyme neuroborreliosis (LNB) might experience lingering symptoms that persist despite antibiotic drug therapy. We tested whether those symptoms are caused by maladaptive immune responses by measuring 20 immune mediators in serum and cerebrospinal fluid (CSF) in 79 LNB patients followed for 1 year. At study entry, most mediators were highly concentrated in CSF, the site of the infection. Those responses resolved with antibiotic therapy, and associations between CSF cytokines and signs and symptoms of LNB were no longer observed. In contrast, subjective symptoms that persisted after use of antibiotics were associated with increased levels of serum interferon-α (IFN-α), which were already observed at study entry, and remained increased at each subsequent timepoint. Highest IFN-α levels corresponded with severe disease. Although the infection serves as the initial trigger, sequelae after antibiotic therapy are associated with unremitting systemic IFN-α levels, consistent with the pathogenic role of this cytokine in interferonopathies in other conditions.

Identifiants

pubmed: 37209716
doi: 10.3201/eid2906.221685
pmc: PMC10202885
doi:

Substances chimiques

Interferon-alpha 0
Cytokines 0
Immunologic Factors 0
Anti-Bacterial Agents 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1091-1101

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI150157
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR043521
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI144916
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

N Engl J Med. 2007 Oct 4;357(14):1422-30
pubmed: 17914043
Neurology. 2003 Jun 24;60(12):1923-30
pubmed: 12821734
J Neurol Sci. 2001 Mar 1;184(2):101-22
pubmed: 11239944
Wien Klin Wochenschr. 2002 Jul 31;114(13-14):544-50
pubmed: 12422599
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
PLoS Pathog. 2022 Mar 24;18(3):e1010365
pubmed: 35324997
J Clin Med. 2018 Dec 02;7(12):
pubmed: 30513820
Clin Infect Dis. 2016 Aug 1;63(3):346-53
pubmed: 27161773
N Engl J Med. 2001 Jul 12;345(2):85-92
pubmed: 11450676
N Engl J Med. 2016 Mar 31;374(13):1209-20
pubmed: 27028911
J Immunol. 2008 Dec 15;181(12):8492-503
pubmed: 19050267
J Public Health (Oxf). 2017 Mar 1;39(1):74-81
pubmed: 26966194
Curr Probl Dermatol. 2009;37:31-50
pubmed: 19367096
Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13498-13507
pubmed: 31209025
Nat Rev Immunol. 2022 Aug;22(8):471-483
pubmed: 34671122
BMC Microbiol. 2016 Mar 08;16:29
pubmed: 26957120
J Clin Invest. 2012 Jul;122(7):2652-60
pubmed: 22728937
J Immunol. 2017 Nov 15;199(10):3525-3534
pubmed: 28986440
Emerg Infect Dis. 2021 Feb;27(2):616-619
pubmed: 33496229
Arthritis Rheum. 2012 May;64(5):1497-507
pubmed: 22246581
Infect Dis Clin North Am. 2015 Jun;29(2):309-23
pubmed: 25999226
Clin Infect Dis. 2021 Oct 5;73(7):e2342-e2349
pubmed: 32975577
Clin Infect Dis. 2014 Apr;58(7):937-45
pubmed: 24523212
Arthritis Rheum. 2011 Aug;63(8):2238-47
pubmed: 21590753
Eur J Neurol. 2010 Jan;17(1):8-16, e1-4
pubmed: 19930447
Clin Infect Dis. 2006 Nov 1;43(9):1089-134
pubmed: 17029130
Nat Rev Rheumatol. 2021 Aug;17(8):449-461
pubmed: 34226730
Clin Vaccine Immunol. 2016 Sep 06;23(9):757-66
pubmed: 27358211
Lancet. 2012 Feb 4;379(9814):461-73
pubmed: 21903253
Biol Psychiatry. 2004 Dec 1;56(11):819-24
pubmed: 15576057
J Neuroimmunol. 2013 Feb 15;255(1-2):85-91
pubmed: 23141748
Neurology. 2008 Mar 25;70(13):992-1003
pubmed: 17928580
Clin Infect Dis. 2012 Aug;55(3):343-50
pubmed: 22523260
J Clin Invest. 2020 May 1;130(5):2148-2151
pubmed: 32281948
Nat Rev Neurol. 2015 Aug;11(8):446-56
pubmed: 26215621
Infect Dis Clin North Am. 2015 Jun;29(2):269-80
pubmed: 25999223
Nat Rev Dis Primers. 2016 Dec 15;2:16090
pubmed: 27976670
Vector Borne Zoonotic Dis. 2011 Jul;11(7):883-9
pubmed: 21083376
BMJ. 2006 Sep 16;333(7568):575
pubmed: 16950834
Clin Infect Dis. 2014 Feb;58(3):372-80
pubmed: 24218102
Pharm World Sci. 2005 Dec;27(6):423-31
pubmed: 16341948

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH